The global endoscopy devices market was valued at approximately USD 61.1 billion in 2024 and is projected to reach USD 76.6 billion by 2030, growing at a CAGR of 3.79% over the forecast period, according to a Grand View Research report updated in October 2024 (Grand View Research, 2024). Within this broader market, flexible endoscopes — including gastroscopes, colonoscopes, bronchoscopes, and duodenoscopes — represent the largest single product segment, accounting for approximately 41% of total market revenue.
These aggregate numbers, however, obscure a more interesting and commercially significant story: the distribution of growth across regions, procedure types, and infrastructure tiers is highly uneven. For anyone operating in the flexible endoscope supply chain — whether as a manufacturer, distributor, repair center, or parts supplier — understanding where growth is concentrated and what is driving it is more valuable than tracking headline market size numbers.
What Is Actually Driving Flexible Endoscope Demand?
Three structural forces are driving endoscope procedure volumes globally, and they are not diminishing:
1. Colorectal Cancer Screening Expansion
Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally and the second leading cause of cancer mortality. Colonoscopy-based screening programs — either opportunistic or organized — are expanding in scope and geographic coverage. The US Preventive Services Task Force lowered the recommended CRC screening age from 50 to 45 years old in 2021, a change estimated to add several million additional eligible patients to the US colonoscopy pipeline annually (USPSTF, 2021). Similar guideline shifts are underway in Europe and parts of Asia Pacific.
2. Rising Gastrointestinal Disease Burden
The incidence of upper and lower GI conditions — including inflammatory bowel disease (IBD), gastric ulcer disease, Barrett’s esophagus, and gastric cancer — is increasing across most major markets, particularly in middle-income countries undergoing dietary and lifestyle transitions. China, India, and Southeast Asia are seeing accelerating IBD incidence that was historically low in these populations. This translates directly into growing flexible upper GI endoscopy procedure volumes in markets where the installed base of endoscope hardware is still being established.
3. Respiratory Disease Monitoring Post-COVID-19
The COVID-19 pandemic, somewhat counterintuitively, expanded the clinical profile of bronchoscopy. Post-COVID pulmonary sequelae — including persistent lung infiltrates, suspected organizing pneumonia, and increased lung cancer surveillance — have driven durable bronchoscopy volume increases in pulmonology departments that have maintained above-pre-pandemic levels through 2024. The simultaneous expansion of robotic bronchoscopy platforms (Auris Health/J&J, Intuitive Surgical) is generating new demand for compatible access scopes and accessories.
Regional Growth Map: Where the Momentum Is
| Region | Growth Profile | Primary Drivers | Key Constraint |
|---|---|---|---|
| North America | Steady; mature market | CRC screening age lowered to 45; AI adoption; robotic bronchoscopy | High OEM capital cost; repair budget pressure |
| Western Europe | Steady; sustainability focus | Organized screening programs; MDR-compliant parts sourcing demand | Single-use waste concerns; EU MDR compliance burden |
| Asia Pacific | 🔺 Fastest growing | Gastric cancer screening (Japan, Korea, China); rising IBD; healthcare infrastructure expansion | Price sensitivity; OEM dominance in tier-1 hospitals |
| Middle East & Africa | Moderate; infrastructure-dependent | Healthcare facility expansion; government health investment programs | Reprocessing infrastructure gaps; trained staff shortage |
| Latin America | Moderate growth | GI disease burden; private hospital expansion | Currency volatility; import cost pressures |
Asia Pacific deserves particular attention. Japan and South Korea have among the most mature organized gastric cancer screening programs in the world — Japan’s nationwide endoscopic gastric cancer screening program covers the majority of the adult population. China is investing heavily in digestive disease infrastructure as GI cancer burden grows. Taken together, Asia Pacific represents both the largest growth opportunity and the most complex competitive environment for flexible endoscope supply chains.
The Market Concentration Problem: Three Companies, Most of the World’s Endoscopes
Global flexible endoscope manufacturing is highly concentrated. Olympus Corporation holds approximately 70% of the global flexible endoscope market; Fujifilm and Hoya (Pentax Medical) account for most of the remaining installed base in GI applications. This oligopoly has significant implications for pricing, parts availability, and the repair ecosystem.
When Olympus divests or discontinues a scope model, the installed base does not disappear — it remains in clinical use for years, while parts availability from the OEM channel diminishes. This is the structural dynamic that created the third-party endoscope parts market: hospitals with aging but functional Olympus, Fujifilm, and Pentax scope fleets need access to replacement components after the OEM spare parts catalog is depleted or restricted.
The 2021 Olympus restructuring, which separated the endoscope business into a dedicated medical devices division, signaled a strategic focus on premium new products — with consequent deprioritization of service and parts support for legacy platforms. For the repair market, this represents an enduring commercial opportunity.
Supply Chain Complexity: What the Last Four Years Have Revealed
The COVID-19 pandemic disrupted flexible endoscope supply chains in ways that exposed structural vulnerabilities that had previously been invisible. Optical component manufacturing, precision lenses, and specialized polymer materials for insertion tube construction are predominantly concentrated in Japan and Germany. When air freight capacity contracted in 2020–2021, endoscope repair lead times extended from weeks to months, forcing facilities to make clinical decisions about scope utilization they would not otherwise have faced.
Post-pandemic, procurement teams have been more attentive to supply chain resilience — seeking parts suppliers with stocked inventory rather than just-in-time sourcing, and qualifying multiple supply relationships for critical components. This shift toward strategic parts inventory management favors specialist parts distributors who maintain physical stock across a broad component range, rather than OEM channels that supply on demand from Japan-based inventory.
“Supply chain resilience for flexible endoscope repair depends on distributed inventory — not just technical expertise. A repair center that cannot access the parts it needs, when it needs them, cannot serve its hospital clients.”
Implications for Procurement and Repair Strategy Through 2030
Drawing together the market dynamics above, several strategic implications are clear for endoscopy departments, biomedical engineering teams, and repair centers planning their 2025–2030 positioning:
- Procedure volumes will grow — driven by CRC screening expansion, GI disease burden, and post-COVID respiratory monitoring. The installed flexible endoscope base will expand, and with it the repair addressable market.
- Legacy scope fleet maintenance will be a persistent need — as OEM channels deprioritize older platforms, third-party parts sourcing becomes the only viable maintenance pathway for aging fleets.
- Asia Pacific growth requires region-appropriate supply partnerships — price-sensitive markets need cost-efficient OEM-compatible parts sourced outside the premium OEM channel.
- Supply chain redundancy is a procurement priority — single-source dependency on OEM spare parts channels is a recognized operational risk, not just a cost management issue.
- MDR and FDA quality requirements are non-negotiable — parts suppliers and repair centers serving regulated markets must operate within documented quality management systems to remain viable partners.
At Medwalt, we build our parts inventory around the scope platforms that will remain in clinical use through this growth cycle. Our catalog of OEM-compatible flexible endoscope components spans Olympus, Fujifilm, and Pentax platforms, with stocked inventory designed for rapid delivery to repair centers and biomedical engineering departments globally. For supply chain planning support or specific component availability inquiries, contact our team.
Key Takeaways
- The global endoscopy devices market will reach USD 76.6 billion by 2030; flexible endoscopes represent ~41% of market revenue.
- CRC screening age reduction, rising GI disease burden, and post-COVID respiratory monitoring are structural demand drivers.
- Asia Pacific is the fastest-growing region, driven by gastric cancer screening programs and expanding healthcare infrastructure.
- Olympus holds ~70% of the global flexible endoscope market — OEM channel constraints on legacy models create durable third-party parts demand.
- Post-pandemic supply chain experience has elevated inventory resilience as a procurement criterion alongside cost and quality.
Medwalt provides OEM-compatible flexible endoscope parts and components with stocked inventory for rapid global delivery. Learn more at medwalt.com.
